Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014
Wolfgang Froestl1, Andreas Muhs1, Andrea Pfeifer1
1AC Immune SA, EPFL, Lausanne, Switzerland.
Abstract:
Scientists working in the fields of Alzheimer's disease and, in particular, cognitive enhancers are very productive. The review "Cognitive enhancers (nootropics): drugs interacting with receptors" was accepted for publication in July 2012. Since then, new targets for the potential treatment of Alzheimer's disease were identified. This update describes drugs interacting with 42 receptors versus 32 receptors in the first paper. Some compounds progressed in their development, while many others were discontinued. The present review covers the evolution of research in this field through March 2014.
More Related Videos
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Drugs Affecting Neurotransmitter Release or Uptake
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Antidepressant Drugs: MAOIs and Other Agents


